Skip to content

Effect of Continuous Remifentanil Infusion on Hemodynamic Responses to Tracheal Intubation During General Anesthesia Induction in Elderly Patients: A Single-center Randomized Controlled Trial

Effect of Continuous Remifentanil Infusion on Hemodynamic Responses to Tracheal Intubation During General Anesthesia Induction in Elderly Patients: A Single-center Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119376
Enrollment
Unknown
Registered
2026-02-26
Start date
2026-03-02
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthetic Induction

Interventions

control group:When the three - way verification is completed and anesthesia induction is initiated, normal saline is continuously infused via a pump immediately after the administration of the analges
experimental group:When the three-way verification is completed and anesthesia induction is initiated, remifentanil injection is continuously administered via a pump at a rate of 0.08 µg/kg·min immedi
pump unit: mL/h
calculation formula: mL/h = 0.08 µg/kg·min × 60 min × body weight in kg). Subsequently, sufentanil injection at a dose of 0.3 µg/kg is slowly administered intravenously (over > 30 seconds), followed b

Sponsors

Meishan People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 65 years. 2. American Society of Anesthesiologists (ASA) physical status classification ?-?. 3. Scheduled surgery with an anticipated duration of more than 30 minutes, and tracheal intubation general anesthesia is feasible based on pre-anesthesia evaluation. 4. Body Mass Index (BMI) ranging from 18 to 25 kg/m². 5. Stably controlled preoperative blood pressure (systolic blood pressure 90–160 mmHg and diastolic blood pressure 55–100 mmHg). 6. Written informed consent signed by the patient or their legal representative.

Exclusion criteria

Exclusion criteria: 1. History of hypersensitivity to remifentanil, sufentanil, etomidate, cisatracurium besilate, or other study-related drugs. 2. Severe cardiac insufficiency (left ventricular ejection fraction [LVEF] < 45%) complicated with high-risk severe arrhythmias (e.g., frequent ventricular premature beats, high-degree atrioventricular block, rapid atrial fibrillation, etc.). 3. Hepatic or renal failure (Child-Pugh class C or estimated glomerular filtration rate [eGFR] < 30 ml/min). 4. Administration of opioids or sedatives within 24 hours before surgery. 5. Cognitive dysfunction that prevents cooperation with the study procedures.

Design outcomes

Primary

MeasureTime frame
The maximum rate of change in systolic blood pressure within 5 minutes after endotracheal intubation compared with the baseline value (the average of three consecutive measurements obtained during a 5-minute resting period before induction);

Secondary

MeasureTime frame
The maximum rate of change in heart rate within 5 minutes after endotracheal intubation compared with the baseline value;The incidence of hypotension (systolic blood pressure 180 mmHg) or systolic blood pressure fluctuation exceeding 30% of the baseline value within 5 minutes after anesthesia induction;The amplitude of difference between the maximum and minimum mean arterial pressure during the anesthesia induction period;The amplitude of difference between the maximum and minimum systolic blood pressure during the anesthesia induction period;Dosage and frequency of administration of vasoactive drugs (e.g., phenylephrine for systolic blood pressure decrease > 30% of the baseline value or systolic blood pressure 180 mmHg or systolic blood pressure increase > 30% of the baseline value);Satisfaction score of the on-duty anesthesiologist (scale: 0–10 points; 5 points = basic satisfaction);

Countries

China

Contacts

Public ContactLi Jie

Meishan People's Hospital

15583980771@163.com+86 155 8398 0771

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026